Compare Crispr Therapeutics AG (CRSP) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs KKR & Co Inc — how do they compare? Crispr Therapeutics AG trades at $50.34 (market cap $4.97B), while KKR & Co Inc trades at $99.55 (market cap $87.28B). The key difference: KKR & Co Inc is far larger — about 17.6× Crispr Therapeutics AG's market cap, and KKR & Co Inc pays a 0.77% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | KKR | |
|---|---|---|
Market Cap | $4.97B | $87.28B |
Sector | Health | Financials |
52-Week High | $76.78 | $152.16 |
52-Week Low | $44.34 | $83.88 |
Enterprise Value | $3.32B | $12.80B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
KKR trades at $96.91, showing minimal daily movement (-0.03%). The stock maintains a bullish technical outlook with strong analyst support (89% buy ratings) and a consensus price target of $122.71, representing 27% upside potential. Recent developments include multiple strategic investments, including a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF Power Solutions' North American operations, signaling aggressive expansion.
KKR demonstrates solid fundamentals with $19.2B revenue and $2.37B net income for 2025. The company shows consistent earnings beats and strong cash flow generation. Key risks include volatile cash flow patterns and high leverage. With robust institutional backing and strategic growth initiatives, KKR appears well-positioned for continued expansion in alternative asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
